Masimo (NASDAQ:MASI) Sets New 1-Year High - Time to Buy?

Masimo Co. (NASDAQ:MASI - Get Free Report) reached a new 52-week high during trading on Thursday . The company traded as high as $181.16 and last traded at $180.71, with a volume of 11511 shares. The stock had previously closed at $177.60.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Stifel Nicolaus reiterated a "buy" rating and set a $190.00 price objective (up previously from $170.00) on shares of Masimo in a research report on Friday, November 22nd. BTIG Research increased their price target on shares of Masimo from $166.00 to $170.00 and gave the company a "buy" rating in a research report on Monday, October 14th. Wells Fargo & Company increased their price target on shares of Masimo from $171.00 to $193.00 and gave the company an "overweight" rating in a research report on Wednesday, December 11th. Raymond James increased their price target on shares of Masimo from $170.00 to $194.00 and gave the company an "outperform" rating in a research report on Friday, December 27th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Masimo in a research report on Wednesday, January 22nd. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $191.40.

Masimo Stock Down 1.2 %

The stock has a market capitalization of $9.22 billion, a PE ratio of 118.72 and a beta of 1.02. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. The company's 50-day moving average is $171.28 and its 200 day moving average is $144.96.

Masimo (NASDAQ:MASI - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.14. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The company had revenue of $504.60 million for the quarter, compared to the consensus estimate of $502.87 million. During the same quarter in the prior year, the company earned $0.63 EPS. Masimo's quarterly revenue was up 5.4% on a year-over-year basis. As a group, analysts anticipate that Masimo Co. will post 4.1 EPS for the current year.

Hedge Funds Weigh In On Masimo

Several hedge funds and other institutional investors have recently bought and sold shares of MASI. FMR LLC lifted its position in shares of Masimo by 41.2% during the 3rd quarter. FMR LLC now owns 6,756,618 shares of the medical equipment provider's stock valued at $900,860,000 after buying an additional 1,970,883 shares in the last quarter. Westfield Capital Management Co. LP lifted its position in shares of Masimo by 23.2% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,394,056 shares of the medical equipment provider's stock valued at $185,869,000 after buying an additional 262,370 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in shares of Masimo by 916.1% during the 4th quarter. Assenagon Asset Management S.A. now owns 216,051 shares of the medical equipment provider's stock valued at $35,713,000 after buying an additional 194,788 shares in the last quarter. Clearline Capital LP purchased a new position in shares of Masimo during the 3rd quarter valued at approximately $21,337,000. Finally, ING Groep NV lifted its position in shares of Masimo by 143.3% during the 3rd quarter. ING Groep NV now owns 240,900 shares of the medical equipment provider's stock valued at $32,119,000 after buying an additional 141,900 shares in the last quarter. Institutional investors and hedge funds own 85.96% of the company's stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.